BTAI - BioXcel Therapeutics, Inc.

1.15
0   0%

Share volume: 859,261
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$1.15
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.17%
1 Month
-21.77%
3 Months
-36.81%
6 Months
-49.12%
1 Year
-31.95%
2 Year
-61.28%
Key data
Stock price
$1.15
P/E Ratio 
N/A
DAY RANGE
$1.13 - $1.23
EPS 
-$7.16
52 WEEK RANGE
$1.01 - $8.08
52 WEEK CHANGE
-$37.84
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
27.075 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-10-2025
NEXT EARNINGS DATE
05-08-2025
BETA 
1.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,133,806
AVERAGE 30 VOLUME 
$1,062,468
Company detail
CEO: Vimal D. Mehta
Region: US
Website: bioxceltherapeutics.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioXcel Therapeutics, Inc. uses artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Recent news